Abstract The CJC-1295 No DAC 5mg peptide pen contains a purified solution of Modified GRF 1-29. This tetra-substituted analogue of Growth Hormone-Releasing Hormone (GHRH) is engineered to resist rapid enzymatic cleavage by DPP-IV, extending its biological half-life from the <7 minutes of native GHRH to approximately 30 minutes. This duration is optimal for mimicking the natural physiological pulsatility of growth hormone secretion. Unlike the “DAC” variant which binds albumin for continuous release, the “No DAC” formulation allows for discrete secretory spikes, making this 5mg formulation the standard control reagent for pulsatile pituitary stimulation and synergistic secretagogue research.

Mechanism and Research Interest

Primary Biological Pathway: Physiological Pulsatility The core research utility of Mod GRF 1-29 is its ability to induce a natural, high-amplitude pulse of Growth Hormone (GH). By binding to the GHRH Receptor on the pituitary somatotrophs, it triggers cAMP signaling only for the duration of its short half-life. This “on-off” signal is critical for preventing receptor downregulation (tachyphylaxis) and mimics the body’s circadian rhythm, contrasting with the “always on” signal of the DAC variant.

Secondary Research Finding: Synergistic Amplification Mod GRF 1-29 is most frequently utilised in “stacking” protocols. Research demonstrates that when co-administered with a Ghrelin-mimetic (like Ipamorelin or GHRP-2), the result is a non-linear, synergistic release of GH. The 5mg formulation allows researchers to precisely titrate the GHRH component of this stack to determine the minimum effective dose required to unlock this synergy.

Tertiary Research Finding: Sleep Architecture Endogenous GHRH is linked to the regulation of Slow-Wave Sleep (SWS). Because Mod GRF 1-29 has a short duration of action, researchers use the 5mg pen to administer bolus doses immediately prior to the sleep cycle in animal models. The goal is to investigate whether enhancing the initial “night pulse” of GH can improve delta-wave activity and sleep quality without elevating daytime cortisol or GH levels.

Long-term Genomic and Safety Observations Safety studies regarding Mod GRF 1-29 focus on the preservation of the pituitary axis. Unlike continuous infusion models which can lead to somatotroph hyperplasia or exhaustion, the pulsatile nature of this peptide maintains the gland’s sensitivity. Genomic analysis confirms that chronic intermittent use does not suppress endogenous Ghrh production to the same extent as long-acting exogenous agents.

Product Specifications

• Purity: Validated at >98+% via High-Performance Liquid Chromatography (HPLC). We strictly verify the presence of the four amino acid substitutions (D-Ala, Gln, Ala, Leu) that confer metabolic stability.

• Appearance: The 3ml pen contains a clear, colourless, sterile liquid.

• Precision: The pen delivery system ensures accurate volumetric dosing. The 5mg concentration is ideal for smaller cohorts or shorter studies where the 10mg “bulk” pen might result in reagent wastage due to expiration after opening.

• Storage: The product must be stored at 2∘C to 8∘C.

Storage and Shipping Guidelines

Refrigeration and Shelf Life The CJC-1295 No DAC 5mg Pen contains a peptide that is sensitive to enzymatic degradation. It must be refrigerated (2∘C to 8∘C). The shelf life is 12 months in the sealed state. Once the pen is accessed, the bacteriostatic environment preserves the solution for 28 days. Because this molecule lacks the albumin-binding protection of the DAC variant, cold-chain maintenance is critical to prevent hydrolysis.

Shipping Stability We utilise medical-grade thermal packaging. The peptide is stable for up to 72 hours at ambient UK temperatures. However, to minimise structural relaxation of the peptide chain, we recommend selecting the fastest available shipping option.

Freezing Warning Do not freeze. Freezing can cause the formation of ice crystals that damage the peptide structure. Upon thawing, the solution may become cloudy. A frozen pen should be considered compromised and discarded.

Why Choose the Peptide Pro 3ml Pen Format?

The CJC-1295 No DAC 5mg Pen is the definitive tool for Controlled Pulsatile Research. While the 10mg pen serves high-throughput labs, the 5mg pen offers a fresh, sterile option for pilot studies or smaller experimental groups.

It eliminates the variability of manual reconstitution, providing a verified concentration that is ready for immediate co-administration with GHRPs. This simplifies the workflow for “stacking” experiments, ensuring that your GHRH:GHRP ratios are accurate and reproducible.

For researchers building a synergistic protocol, we recommend examining:

• Ipamorelin 10mg:  (The selective partner for a “No Side Effect” stack).

• GHRP-2 5mg: (A matched-capacity pen for higher potency stacks).

• CJC-1295 with DAC 5mg:  (To compare pulsatile vs. continuous pharmacokinetics).

Disclaimer

This product is strictly for Research Use Only (RUO). It is not intended for human consumption, injection (e.g., for anti-ageing, bodybuilding, or sleep enhancement), therapeutic use, or diagnostic procedures. The information provided is for educational and scientific reference only. Purchase is restricted to verified research institutions and qualified individuals. Any evidence of intended misuse for human application will result in immediate order cancellation and blacklisting, in compliance with UK research chemical regulations.